Effects of Acute and Chronic Infusion of Islet Amyloid Polypeptide on Food Intake in Rats
- 1 January 1996
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 31 (1) , 83-89
- https://doi.org/10.3109/00365529609031632
Abstract
Background: Islet amyloid polypeptide (IAPP), also called amylin, is a hormonal peptide produced by the islet β-cells of the pancreas. Because the peptide is co-stored and co-released with insulin, attention has been focused on IAPP's ability to interfere with glucose metabolism. However, IAPP also has other effects, such as a reduction of food intake. Methods: In this study we investigated the dose-response effect of acute systemic administration of rat and human IAPP on food intake, and the cumulative effect of chronically increased circulating IAPP concentrations on food intake and body weight in the rat. Results: All doses of rat IAPP investigated acutely inhibited food intake. The lowest infusion rate of 8 pmol/kg/min caused an 28% inhibition of the food intake at 2 h (p < 0.05). No effect of human IAPP was observed. Chronic administration of rat IAPP via an osmotic minipump during a 6-day period caused prolonged inhibitory effects on food intake and reduced body weight. During the first 3 days of infusion the food intake of the IAPP group was only 44% of the food intake of the control group (p < 0.001). The body weight of the IAPP group had fallen 18.6 ± 2.7 g by day 3, in contrast to a small increase in the control group (4.0 ± 3.1 g; p < 0.001). The reduction in food intake was sustained throughout the last 3 days of study (IAPP, 16.7 ± 1.1 g/day; control, 20.6 ± 1.5; p < 0.05). Similarly, the body weight still differed at the end of day 6 and, compared with day 0, was -8.7 ± 3.7 g for the IAPP group and + 10.9 ± 4.8 for the control group (p < 0.01). Conclusions: These findings show that chronic increase of circulating IAPP levels can cause a marked reduction in both food intake and body weight and, together with the reduced food intake seen after acute administration of the peptide, indicates the possibility of IAPP functioning as a satiety factor.Keywords
This publication has 28 references indexed in Scilit:
- Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and DiabetesNew England Journal of Medicine, 1994
- Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1991
- Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogsDiabetologia, 1990
- In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbitBiochemical and Biophysical Research Communications, 1989
- Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic isletsDiabetologia, 1989
- Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitroNature, 1988
- Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.Proceedings of the National Academy of Sciences, 1987
- Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells.Proceedings of the National Academy of Sciences, 1987
- A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreasBiochemical and Biophysical Research Communications, 1986
- The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitusDiabetologia, 1978